Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Entospletinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kronos blames enrollment troubles for ending phase 3 AML program
    Kronos blames enrollment troubles for ending phase 3 AML program

    10 Nov 2022

    // James Waldron FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/time-runs-out-kronos-phase-3-aml-drug-biotech-blames-enrolment-struggles-ending-trial

    James Waldron FIERCEBIOTECH
    10 Nov 2022
    Share Share
    Kronos Bio and Invivoscribe Partner for Use with Entospletinib
    Kronos Bio and Invivoscribe Partner for Use with Entospletinib

    16 Aug 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/kronos-bio-and-invivoscribe-partner-on-companion-diagnostic-for-use-with-entospletinib-kronos-bios-investigational-compound-being-developed-for-patients-with-aml-301606955.html

    PRNEWSWIRE
    16 Aug 2022
    Share Share
    Kronos Bio's SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022
    Kronos Bio's SYK Inhibitors Entospletinib and Lanraplenib at EHA 2022

    12 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/12/2442168/0/en/Kronos-Bio-s-Investigational-SYK-Inhibitors-Entospletinib-and-Lanraplenib-to-be-Featured-in-Four-Poster-Presentations-at-EHA2022-Congress.html

    GLOBENEWSWIRE
    12 May 2022
    Share Share